lintuzumab,venetoclax
abbvie,roche,actinium pharma
['bet', 'leusm', 'venetoclax', 'lintuzumab', 'leukemia']
#ash22 #leusm abedin: 12m os 53%, 24m 32% better when used in 1st/2nd salvage, 61% at 12m and 49% at 24m. in those who achieved mrd neg cr 89% and 49% respectively. encouraging responses in tp53m. need study of clag-m/lintu as first salvage with bridge to allo. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)